Hosted on MSN1mon
Alector stock drops after Alzheimer’s drug fails in Phase II trialAlector’s internal pipeline suffered a blow as the Phase II INVOKE-2 trial evaluating its Alzheimer’s disease therapy, AL002, failed to meet the primary endpoint. The therapy failed to slow ...
Mizuho has recently reduced Alector Inc (ALEC) stock to Neutral rating, as announced on December 17, 2024, according to Finviz. Earlier, on December 16, 2024, Stifel had reduced the stock from a Buy ...
Alector, Inc. (NASDAQ:ALEC – Get Free Report) has been given a consensus recommendation of “Hold” by the seven research firms ...
On Monday, Alector Inc (ALEC) stock saw a modest uptick, ending the day at $1.92 which represents a slight increase of $0.06 or 3.23% from the prior close of $1.86. The stock opened at $1.87 and ...
Alector (ALEC – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Jeffrey Hung from Morgan Stanley downgraded the rating on the stock to a ...
Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal. H.C. Wainwright analyst Andrew Fein ...
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the ...
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Alector (ALEC – Research Report), reducing the price target to $7.00. Don't Miss our Black Friday Offers: Andrew Fein’s rating ...
Mizuho analyst Graig Suvannavejh downgraded Alector (ALEC) to Neutral from Outperform with a price target of $2.50, down from $9. Following the negative Phase 2 INVOKE-2 results for AL002 ...
Alector, Inc. (NASDAQ:ALEC – Get Free Report) was the recipient of a large growth in short interest in November. As of November 30th, there was short interest totalling 5,390,000 shares ...
Hosted on MSN1mon
Morgan Stanley Downgrades Alector (ALEC)Fintel reports that on November 26, 2024, Morgan Stanley downgraded their outlook for Alector (NasdaqGS:ALEC) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 254.17% Upside As of ...
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback